Sunday, 29 November 2020

Agilent receives FDA approval for companion diagnostic assay

19 June 2019 | News

The assay is now approved as an aid in identifying patients with head and neck squamous cell carcinoma

image credit- istock.com

image credit- istock.com

Agilent Technologies Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx assay for expanded use. The assay is now approved as an aid in identifying patients with head and neck squamous cell carcinoma (HNSCC) for treatment with KEYTRUDA (pembrolizumab), anti-PD-1 therapy manufactured by Merck.

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-approved test.

PD-L1 IHC 22C3 pharmDx is the only companion diagnostic FDA-approved to aid in the identification of HNSCC patients for treatment with KEYTRUDA. HNSCC is the fifth cancer type for which PD-L1 IHC 22C3 pharmDx has gained FDA approval in the United States.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account






Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls